Corvus Pharmaceuticals, Inc. (CRVS) Dividend History

Company News

• US Stocks To Open Higher As Rate Cut Expectations Surge: All Eyes On Dow Jones To Break Its 9-Day Losing Streak

  U.S. stock futures climbed on Wednesday as investors await the Federal Reserve's interest rate decision and economic data releases. The Dow Jones index extended its losing streak to nine consecutive sessions, the longest since 1978.

  Benzinga

  Featured Companies: APDN
• Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

  Corvus Pharmaceuticals presented new preclinical data showing that their lead ITK inhibitor, soquelitinib, can prevent lung damage, inflammation, and pulmonary hypertension in mouse models of systemic sclerosis, an autoimmune disease. The data supports the potential of ITK inhibition as a novel therapeutic approach for immune-mediated fibrotic diseases.

  GlobeNewswire Inc.
• Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

  Corvus Pharmaceuticals presented new data at the SITC Annual Meeting showing that their drug ciforadenant has the potential to overcome resistance to immunotherapy in metastatic castration-resistant prostate cancer. The data suggests ciforadenant can reduce immunosuppression and enhance sensitivity to anti-PD1 therapy.

  GlobeNewswire Inc.
• T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - Regulatory Support Drives Fast-Track Development of Novel T Cell Lymphoma Drugs from Eisai, Takeda, and Rhizen Pharmaceuticals

  The article discusses the T-cell lymphoma drug pipeline, highlighting the development of novel therapies by companies like Eisai, Takeda, and Rhizen Pharmaceuticals. Regulatory agencies are providing support to accelerate the development of these treatments, addressing the urgent need for better options in this challenging condition.

  GlobeNewswire Inc.

  Featured Companies: RIGL
• Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

  Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024

  GlobeNewswire Inc.